

Contents

<i>Preface</i>	<i>iii</i>
<i>Contributors</i>	<i>ix</i>
<i>Useful Information</i>	<i>xiii</i>
1. Introducing Pharmacokinetic and Pharmacodynamic Concepts <i>Malcolm Rowland</i>	1
2. In Vitro Enzyme Kinetics Applied to Drug-Metabolizing Enzymes <i>Kenneth R. Korzekwa</i>	33
3. Human Cytochromes P450 and Their Role in Metabolism-Based Drug–Drug Interactions <i>Stephen E. Clarke and Barry C. Jones</i>	55
4. Review of Human UDP-Glucuronosyltransferases and Their Role in Drug–Drug Interactions <i>Rory P. Remmel</i>	89
5. Drug–Drug Interactions Involving the Membrane Transport Process <i>Hiroyuki Kusuvara and Yuichi Sugiyama</i>	123

6. In Vitro Models for Studying Induction of Cytochrome P450 Enzymes 189
Jose M. Silva and Deborah A. Nicoll-Griffith
7. In Vitro Approaches for Studying the Inhibition of Drug-Metabolizing Enzymes and Identifying the Drug-Metabolizing Enzymes Responsible for the Metabolism of Drugs 217
Ajay Madan, Etsuko Usuki, L. Alayne Burton, Brian W. Ogilvie, and Andrew Parkinson
8. The Role of P-Glycoprotein in Drug Disposition: Significance to Drug Development 295
Matthew D. Troutman, Gang Luo, Liang-Shang Gan, and Dhiren R. Thakker
9. The Role of the Gut Mucosa in Metabolically Based Drug-Drug Interactions 359
Kenneth E. Thummel and Danny D. Shen
10. Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro-In Vivo Correlations 387
David R. Jones and Stephen D. Hall
11. Prediction of Metabolic Drug Interactions: Quantitative or Qualitative? 415
Jiunn H. Lin and Paul G. Pearson
12. In Vivo Probes for Studying Induction and Inhibition of Cytochrome P450 Enzymes in Humans 439
Grant R. Wilkinson
13. Molecular Modeling Approaches to Predicting Drug Metabolism and Toxicity 505
Anton M. ter Laak, Marcel J. de Groot, and Nico P. E. Vermeulen
14. Development of a Metabolic Drug Interaction Database at the University of Washington 549
Sonia P. Carlson, Isabelle Ragueneau-Majlessi, Thomas E. Bougan, and René H. Levy

15.	Drug–Drug Interactions: Clinical Perspective <i>David J. Greenblatt and Lisa L. von Moltke</i>	565
16.	Drug–Drug Interactions: Toxicological Perspectives <i>Sidney D. Nelson</i>	585
17.	An Integrated Approach to Assessing Drug–Drug Interactions: A Regulatory Perspective <i>Shiew-Mei Huang, Peter Honig, Lawrence J. Lesko, Robert Temple, and Roger Williams</i>	605
18.	Drug–Drug Interactions: Marketing Perspectives <i>Kevin J. Petty and José M. Vega</i>	633
	<i>Index</i>	645